ABSTRACT. Laponite clay is able to retain dexamethasone by simple physisorption, presumably accomplished by hydrogen bonding formation and/or complexation with sodium counterions, as shown by solid state NMR. The physisorption can be somehow modulated by changing the solvent in the adsorption process. This simple system is able to deliver dexamethasone in a controlled manner to solutions used as models for vitreous humor. The proved biocompatibility of laponite as well as its transparency in the gel state, together with the simplicity of the preparation method, make this system suitable for future in vivo tests of ophthalmic treatment.
Introduction
Among the treatments for posterior segment ocular diseases, intravitreal injection is considered an effective approach, as it delivers the therapeutic agent directly into the eye [1, 2] . In spite of some advantages with respect to systemic administration, such as lower side effects, intravitreal injection presents some potential risks associated to the need for repeated injections [3] . In the last years, alternative drug delivery systems are being developed to overcome this kind of limitations by reducing the frequency of injections, and hence the potential complications [4] [5] [6] . For example, dexamethasone (DEX) has been released from biodegradable subconjunctival implants of a poly(ortho ester) [7] , from intravitreal implants of poly((-caprolactone) [8] , or poly(lactic-co-glycolic acid) [9] . The degradation of the polymeric matrix produces the slow release of DEX, but this methodology requires a surgical intervention to implant the material [8, 10] .
Very recently an intravitreal injectable implant has been described using DEX encapsulated into a thermogel matrix of poly(lactic acid-co-glycolic acid)-poly(ethylene glycol)-poly(lactic acid-co-glycolic acid) triblock copolymer, able to lengthen the ocular retention time of DEX from several hours to more than one week [11] . In this case the matrix was prepared by copolymerization of lactic acid and glycolic acid, using poly(ethylene glycol) as initiator. Other hydrogels based on poly(ethylene glycol) and poly(valerolactone) [12] or hyaluronic acid [13, 14] have been also used for DEX release, but not in ophthalmic applications.
Clay minerals play different roles in health care formulations [15, 16] , mainly for topical and gastrointestinal diseases, but only recently they have been envisaged as drug delivery modulators [17] [18] [19] . Natural clays show a certain degree of variability in their properties, such as chemical composition, particle size, and color. Hence, it is very difficult to envisage their use in intravitreal applications, and only in one case they have been used as components of polyurethane composites for implants releasing dexamethasone acetate upon degradation of the polymer [20] . However, synthetic clays are prepared with reproducible composition and textural properties. As an example, laponite (LAP) is a white synthetic smectite clay, a layered hydrous magnesium silicate with an empirical formula of Na0.7[(Si8Mg5.5Li0.3)O20(OH)4] that forms transparent colloidal dispersions in water [21] . As sodium cations are exchangeable, this property has been used to immobilize cationic drugs, usually molecules with protonated amino groups, that can be released in aqueous saline 3 solutions. This is the case of itraconazole [22] (anti-fungal drug), donepezil [23] (Alzheimer's disease), tetracycline [24] (antimicrobial agent), and doxorubicin [25] (antitumoral). In vivo studies with the doxorubicin-laponite system have shown a high antitumor efficacy of the system with very low toxicity [26] , whereas the laponite disks can be modified with folic acid for targeted drug delivery [27] .
Here, we describe the first report of immobilization a non-ionic drug, dexamethasone, on laponite clay, the nature of the drug-clay interaction and the in vitro behavior of the material in controlled delivery.
Materials and methods

Materials
Dexamethasone (DEX) was from Aldrich. Laponite (LAP) was from Rockwood Additives.
Ethanol, acetone and acetonitrile were HPLC grade from Scharlab. CD2Cl2, CD3OD, acetoned6 and dmso-d6 were from Aldrich. Sodium hyaluronate 3% solution (Healon EndoCoat OVD) was from Abbott Medical Optics. Saline solution (9 mg/mL NaCl) was from Fresnius Kabi España.
Preparation and characterization of DEX/LAP
The required amount of DEX (20, 10 or 5 mg) was dissolved in ethanol or acetone (10 mL) and LAP (100 mg) was added to this solution. The slurry was stirred at room temperature for 1 h and then the solvent was removed in a rotary evaporator. In that way, the whole amount of DEX was deposited on the laponite support. The solid was dried at room temperature overnight under vacuum over P2O5. DEX contents were assessed (less than 0.5% error) by carbon analysis of the dried powders in a Perkin-Elmer EA-2400 Series II elemental analyzer. Extraction of the samples with acetonitrile for 1 h led to the complete release of DEX to solution, as determined by HPLC (see below). FT-IR spectra (250 scans) of KBr pellets were registered using a ThermoNicolet Nexus 5700 spectrometer in the range from 4000 to 600 cm -1 at a resolution of 4 cm 1 .
13
C CP-MAS NMR (cross-polarization magic angle spinning nuclear magnetic resonance) spectra were recorded in a Bruker Avance III WB400 spectrometer with 4 mm zirconia rotors spun at magic angle in N2 at 10 kHz. Spectra (1000-25000 scans depending on 4 the sample) were measured using a 1 H /2 pulse length of 3 s, with a contact time (ramp) of 3 ms, spinal64 proton decoupling sequence of 5.3 s pulse length and recycle delay of 7 s.
Dipolar dephasing (DD) spectra were recorded under the same conditions with a dephasing delay of 50 s and a refocusing 13 C  pulse of 8 s. Solution NMR spectra were recorded in a Bruker Avance 400 spectrometer.
Step scanned (1s/step) X-ray diffraction patterns were collected in the Servicio de Difracción de Rayos X y Análisis por Fluorescencia del Servicio
General de Apoyo a la Investigación de la Universidad de Zaragoza at room temperature from 3º in 2 up to 35º, using a D-Max 2500 Rigaku system with a rotating anode. CuK radiation with a wavelength of 1.54 Å at 40 kV and 80 mA was used.
In vitro DEX release studies
Release was studied in two extraction media, saline solution and a model of vitreous humor The presence of laponite in the supernatant was not detected in any case.
Results and discussion
Characterization of adsorbed DEX
In contrast with other drugs immobilized on LAP [22] [23] [24] [25] , DEX is not cationic and it cannot interact with the solid surface through electrostatic forces. Thus, it was deposited on LAP by suspending the clay in an ethanol solution of the drug, with three different DEX/LAP weight ratios, 1:20, 1:10 and 1:5, labeled as low, medium and high, as the optimal situation would be the use of the minimum amount of support for intravitreal injections. The solids were obtained by simply evaporating the solvent under reduced pressure.
As the immobilization of DEX on LAP cannot be due to electrostatic interactions through the exchange of sodium cations, the distribution of DEX on the surface is not easily predictable.
X-ray diffraction was used to determine whether the dexamethasone molecules were able to enter the interlayer space of laponite, leading to an increase in the basal spacing of the clay.
As can be seen in Figure 1A , the powder patterns are poorly oriented, and the 001 line is not Figure S5 ) [31] , according to the decrease in electronic density when accepting a hydrogen (deuterium) bond.
In the case of the solid state 13 C CP-MAS NMR spectrum of DEX, the signals were assigned (Figure 4 ) according to the dipolar dephasing (DD) experiment ( Figure S6 ) combined with the assignment from the spectra in solution. In Table 1 The signals in the 13 C CP-MAS NMR spectrum of DEX(high)/LAP ( Figure 5 ) were also assigned according with the DD spectrum ( Figure S8 ). The chemical shifts are gathered in Table 1 and it can be seen that they are significantly different from those of pure DEX. 
In vitro DEX release from LAP
Vitreous humor is made up of 99% water with a saline content of about 0.9% [33] , thus saline solution was chosen as a first approach to a vitreous model. As vitreous volume in rabbit is around 1.4-1.7 mL [34] , the experiments of DEX delivery were carried out in 2 mL of saline solution by suspending 20 mg of solid. In this way the introduced amounts of DEX, 0.95, 1.82 and 3.33 mg for low, medium and high content DEX/LAP respectively, were by far superior to the toxic dose in rabbits (0.4 mg [35] ), just to test if the amount present in solution reached that limit value. In this case the release mechanism should be the quite fast equilibrium between the physisorbed and the dissolved DEX, with further release once the DEX in solution is consumed. In a first set of experiments with DEX(high)/LAP and DEX(low)/LAP, after equilibration for 24 or 48 h under stirring, the solid was separated by ultracentrifugation (14000 rpm, 20 min), the supernatant was analyzed by HPLC and the solid was suspended again in a new volume of saline solution to simulate the consumption of 13 dissolved DEX in the vitreous humor in the eye. The average of the amounts release at the two equilibration times, with the error bars, is represented in Figure 6 . As can be seen, the amounts released lead to concentrations below the reported solubility of dexamethasone in water (0.08-0.1 mg/mL). This result demonstrates the reproducibility of the in vitro measurements, as well as the role of laponite in the release control, in spite of the lack of any strong electrostatic interaction. This result contrasts with other described methods, using microparticles to encapsulate dexamethasone [36] , in which DEX is immediately released according to its solubility in the extraction medium. Only in the case of the high loading sample, the obtained concentration (up to 0.07 mg/mL) is close to the DEX solubility. These experiments do not fulfil the sink conditions, that prevent reaching concentrations too close to the solubility limit. However, those conditions are used to prevent the effect of the concentration to the release rate in kinetic release experiments. In our case, we are dealing with thermodynamic experiments, as much close as possible to the real situation, in which it would be desirable the presence of a large amount of drug, with a limited amount of liquid phase (vitreous humor), to minimize the number of intraocular injections. Given the role of LAP demonstrated in the first set of results of extractions in saline, it was decided to test a liquid medium more similar to the vitreous humor. Taking into account that the characteristic viscosity of vitreous is attributed to the presence of hyaluronic acid and collagen [37] , we tried to mimic its physical properties by using sodium hyaluronate in saline solution. As the vitreous viscosity is in the range 300-2000 cP, it is necessary to use a concentration of at least 0.5% of sodium hyaluronate in saline solution to reach a viscosity that falls into this range [38] . Hence, the solid sample with medium loading (DEX/LAP = 1:10 w/w) was successively treated with 2 g of solution of hyaluronic acid in saline solution Given the probable role of hydrogen bonding in the retention mechanism of DEX on LAP, the solvent used for DEX deposition (ethanol) could compete with the drug and reduce the DEX-LAP interaction. To check this possibility, the adsorption solvent was changed to acetone in an attempt to enhance the interaction of DEX with the surface. The same three loadings were tested in the release to saline solution and in Figure 9 the results are compared with those obtained with the solids prepared in ethanol.
As can be seen, the desorbed amount is always lower than in the case of ethanol, with an earlier deviation from the linearity, showing that the interaction between dexamethasone and the laponite surface is slightly stronger, and the release is slower. However, the CP-MAS NMR spectrum of DEX/LAP prepared from acetone solution did not reveal any significant difference in chemical shifts. Only slightly broader signals were obtained, a fact that can be explained by a lower mobility of the molecules on the solid or by the existence of a larger number of different adsorption modes.
Conclusion
In this work we have demonstrated that non-ionic drugs, such as dexamethasone, can be retained on laponite, mainly through hydrogen bonding involving hydroxyl and carbonyl groups. The drug is slowly released to saline solutions, as models for vitreous humor, and the 
